PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22847201-2	2012	We analyzed the correlation between the CYP2C9 genotype and cholesterol-lowering effect of fluvastatin in human hypercholesterolemic patients.	Cholesterol	60-71	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	40-46	
18971317-10	2009	Activation of hCAR and hPXR by atorvastatin and the subsequent induction of not only CYP2B6 and CYP3A4 but also of CYP2C9 present an additional target by which atorvastatin, a widely used cholesterol-lowering drug, can modify the kinetics of numerous drugs.	Cholesterol	188-199	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	115-121	
12891229-0	2003	Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.	Cholesterol	62-73	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	13-19	
12891229-19	2003	CONCLUSIONS: The pharmacokinetics of both enantiomers of fluvastatin depended on the CYP2C9 genotype, with a 3-fold group mean difference in the active enantiomer and even greater differences in the inactive enantiomer, but differences in plasma concentrations were not reflected in cholesterol lowering after 14 days of fluvastatin intake in healthy volunteers.	Cholesterol	283-294	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	85-91